Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?
No Thumbnail Available
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes? An RCT demonstrates that dapagliflozin produces better cardiovascular outcomes than placebo for heart failure patients with and without diabetes. PRACTICE CHANGER: Prescribe dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, 10 mg/d in addition to standard therapies for adult patients with heart failure (HF) with a reduced ejection fraction (≤ 40%) and New York Heart Association (NYHA) class II or greater, regardless of type 2 diabetes history, due to improved heart failure and cardiovascular outcomes. (1) STRENGTH OF RECOMMENDATION: B: Based on a single randomized controlled trial.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.